From genome guardian to immune modulator: the dual faces of DNA-PKcs
Bioscience Reports · 18.11.2026 · 46 (11)
DOI: 10.1042/bsr20260587 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Bioscience Reports, online erschienen am 11.11.2026. Verfasst von Qiang Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Protein Structure and Function, Institute of Medicine and Pharmacy, Qiqihar Medical University, Qiqihar, Heilongjiang 161006, China. Hauptthemen laut MEDLINE: DNA-Activated Protein Kinase, Nuclear Proteins. Die Arbeit nennt 136 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: | Natural Science Foundation of Heilongjiang Province (Heilongjiang Natural Science Foundation), Education Department Foundation of Heilongjiang Province, Qiqihar Medical Institute Foundation.
Abstract (Originalsprache)
The DNA-dependent protein kinase catalytic subunit (DNA-PKcs) has long been recognized as a genome guardian, serving as a master regulator of non-homologous end joining (NHEJ), safeguarding genomic integrity and enabling adaptive immunity through V(D)J recombination. Beyond this nuclear function, DNA-PKcs is now increasingly appreciated as a context-dependent immune modulator, acting at the interface between the DNA damage response and inflammatory signaling. This review synthesizes recent advances that redefine DNA-PKcs as a versatile “molecular integrator.” We delineate its structural dynamics and multifaceted regulation, and dissect its dual function in the cytoplasm, where it can either potentiate or suppress the cyclic GMP–AMP synthase and stimulator of interferon genes (cGAS–STING) pathway and even initiate STING-independent interferon responses. We further explore how dysregulation of DNA-PKcs underpins a spectrum of pathologies, from immunodeficiency and autoimmunity to cancer and neurodegeneration. Finally, we discuss the translational promise of DNA-PKcs inhibitors, which not only act as classical chemo- and radio-sensitizers but also remodel the tumor microenvironment by activating antitumor immunity. Decoding the context-dependent logic behind these dual faces is therefore paramount for developing novel therapeutics that leverage DNA-PKcs across oncology, autoimmunity, and neurodegeneration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Protein Structure and Function, Institute of Medicine and Pharmacy, Qiqihar Medical University, Qiqihar, Heilongjiang 161006, China.
- School of Medical Technology, Qiqihar Medical University, Qiqihar, Heilongjiang 161006, China.
- Laboratory of Experimental Diagnosis, the Second Affiliated Hospital of Qiqihar Medical University, Qiqihar, Heilongjiang 161006, China.
ORCID-Profile: Tao Wang
Förderung
- | Natural Science Foundation of Heilongjiang Province (Heilongjiang Natural Science Foundation)
- Education Department Foundation of Heilongjiang Province
- Qiqihar Medical Institute Foundation
- Construction Project of Dominant Characteristic Disciplines of Qiqihar Medical University
- Program for Outstanding Youth Science and Technology Innovation Talent of Qiqihar Medical University
- 黑龙江省科技| Natural Science Foundation of Heilongjiang Province
Zitieren
APA
Li, Q., Zhan, P. W., Hong, X., Qu, Y., & Wang, T. (2026). From genome guardian to immune modulator: the dual faces of DNA-PKcs. Bioscience Reports, 46(11). https://doi.org/10.1042/bsr20260587
Vancouver
Li Q, Zhan PW, Hong X, Qu Y, Wang T. From genome guardian to immune modulator: the dual faces of DNA-PKcs. Bioscience Reports. 2026;46(11). doi:10.1042/bsr20260587
BibTeX
@article{Li2026,
author = {Li, Qiang and Zhan, Pei-Wen and Hong, Xian and Qu, Ying and Wang, Tao},
title = {From genome guardian to immune modulator: the dual faces of DNA-PKcs},
journal = {Bioscience Reports},
year = {2026},
volume = {46},
number = {11},
doi = {10.1042/bsr20260587}
}
EUVIMED